NAMPT as a therapeutic target against stroke  

出　　处：《中国药理学通报》2015年第B11期169-169,共1页Chinese Pharmacological Bulletin

摘　　要：Aim Nicotinamide phosphoribosyltransferase （NAMPT）, also an adipokine known as visfatin, acts via enzymatic activity to synthesize nicotinamide mononucleotide （NMN） and then maintain homeostasis of nicotinam- ide adenine dinucleotide （NAD）, which plays a dual role in energy metabolism and biological signaling. Of note, the NAMPT metabolic pathway connects NAD-dependent sirtuin signaling, constituting a strong intrinsic defense system against various stresses. Most recently, we and others have demonstrated several mechanisms by which NAMPT might serve as a therapeutic target against ischemic stroke, including cerebroprotection in the acute phase as well as vascular repair and neurogenesis in the chronic phase. The molecular mechanisms underlying these bene- fits have been explored in vivo and in vitro for neural cells, endothelial progenitor cells, and neural stem cells. Therapeutic interventions using NMN, NAMPT activators and ischemic conditioning are promising for stroke salvage and rehabilitation. Here, we discuss the current NAMPT data in the context of translational efforts for stroke treat- ment.

关 键 词：STROKE therapeutic targets NAMPT ADIPOKINES NICOTINAMIDE MONONUCLEOTIDE NAD 

分 类 号：R[医药卫生]